
-
Avenue Therapeutics OTC Markets OTCPK:ATXI Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; and intravenous tramadol for the treatment of post-operative acute pain. It also develops BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Location: 1111 Kane Concourse, Bay Harbor Islands, FL, 33154, United States | Website: https://www.avenuetx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-3.91M
Cash
3.502M
Avg Qtr Burn
-1.773M
Short % of Float
2.11%
Insider Ownership
18.41%
Institutional Own.
3.15%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
IV Tramadol Details Pain, Post operative acute pain | Phase 3 Initiation | |
BAER-101 Details Anxiety Disorders, Epilepsy | Phase 2a Initiation | |
AJ201 Details Huntington's disease, Spinal and bulbar muscular atrophy , Spinocerebellar Ataxia, Kennedy's Disease | Phase 1/2 Update |